June 12, 2020
Cue Health says it has received an Emergency Use Authorization (EUA) for its rapid, point-of-care COVID-19 test.
June 10, 2020
Cue Health raises a $100,000,000 series C round from Decheng Capital.
Cue Health raises a $13,000,000 grant from Biomedical Advanced Research and Development Authority.
Cue Health raises a $102,600,000 series C round from ACME Capital, Decheng Capital, Foresite Capital, Johnson & Johnson Innovation – JJDC and Madrone Capital Partners.
Cue Health raises a $45,000,000 series B round from BABEL Ventures, Cove Investments, Dentsu Ventures, Johnson & Johnson, Pritzker Group Venture Capital, Rohan Oza, Section 32, Sherpa Capital, Synergy Ventures and Troy Capital Partners.
Cue Health raises a $15,500,000 series B round from Flat World Partners, MaC Venture Capital, Rohan Oza and Sherpa Capital.
Cue Health raises a $7,500,000 series A round from Immortalana, Jim Messina, Leonardo DiCaprio, Marc Benioff and Sherpa Capital.
Documentaries, videos and podcasts
March 8, 2021
One year into the pandemic, the FDA has authorized its first molecular COVID-19 diagnostic that can be performed completely at home and purchased without a prescription.
November 19, 2020
The U.S. Department of Health and Human Services (HHS) has launched a pilot program with five states to use portable, cartridge-based COVID-19 molecular test kits that provide rapid results. The pilot program will assess how to best integrate diagnostic technology developed by Cue Health, Inc., into strategies for disease surveillance and infection control in institutions such as nursing homes. Used successfully as the primary molecular point-of-care (POC) test to control the spread of CO...
June 12, 2020
Fresh off a $100 million Series C funding round, molecular diagnostics startup Cue Health has more good news - it has received an Emergency Use Authorization (EUA) for its rapid, point-of-care COVID-19 test. The company got a $13 million grant from BARDA in March to help it scale its development and deployment of rapid diagnostics, [...]
March 31, 2020
Biotech startup Cue Health has secured a $13 million contract from the U.S. Department of Health and Human Service' Biomedical Research and Development Authority (BARDA), which will be used to speed the development and testing of a handheld molecular test that can detect the presence of the SARS-CoV-2 novel coronavirus that causes COVID-19. Cue, which [...]